NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $29.50 +10.43 (+54.69%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Edgewise Therapeutics Stock (NASDAQ:EWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$24.84▼$29.9550-Day Range$15.88▼$22.8752-Week Range$5.12▼$30.00Volume11.93 million shsAverage Volume938,707 shsMarket Capitalization$2.76 billionP/E RatioN/ADividend YieldN/APrice Target$33.40Consensus RatingBuy Company OverviewEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More… Imminent FDA Decision Could End Obesity in America... (Ad)This drug could end obesity in America... ...and spark a 224,000% sales surge for one tiny micro-cap stock. Channelnomics says it "Could have a greater impact on the world than artificial intelligence."Get the name of this stock here >>> Edgewise Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 39th PercentileEdgewise Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 766th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEdgewise Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edgewise Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.48) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -19.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -19.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 6.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.34% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 21.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.34% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 21.56%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentEdgewise Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Edgewise Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for EWTX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.11% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Edgewise Therapeutics' insider trading history. EWTX Stock News HeadlinesEdgewise Therapeutics Soars 50%: Key Reasons Behind the SurgeEdgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead.September 19 at 2:15 PM | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume IncreaseSeptember 19 at 9:19 PM | americanbankingnews.comImminent FDA Decision Could End Obesity in America...This drug could end obesity in America... ...and spark a 224,000% sales surge for one tiny micro-cap stock. Channelnomics says it "Could have a greater impact on the world than artificial intelligence."September 19, 2024 | Behind the Markets (Ad)Edgewise Therapeutics Shares Rise on Positive Results for Heart-Disease TreatmentSeptember 19 at 7:47 PM | marketwatch.comEdgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)September 19 at 7:47 PM | seekingalpha.comWhy Edgewise Therapeutics Stock Is Up 50% on ThursdaySeptember 19 at 12:55 PM | fool.comEdgewise Therapeutics Target of Unusually Large Options Trading (NASDAQ:EWTX)September 19 at 12:20 PM | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Sets New 1-Year High at $27.51September 19 at 11:19 AM | americanbankingnews.comSee More Headlines EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX stock has increased by 169.7% and is now trading at $29.50. View the best growth stocks for 2024 here. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its earnings results on Thursday, August, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Top institutional investors of Edgewise Therapeutics include Novo Holdings A S (6.79%), Frazier Life Sciences Management L.P. (3.99%), Perceptive Advisors LLC (1.99%) and Driehaus Capital Management LLC (1.35%). Insiders that own company stock include Peter A Thompson, Orbimed Advisors Llc, Holdings A/S Novo, R Michael Carruthers, Joanne M Donovan, Kevin Koch, Behrad Derakhshan, Alan J Russell and John R Moore. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/19/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$33.40 High Stock Price Target$48.00 Low Stock Price Target$25.00 Potential Upside/Downside+28.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.01% Return on Assets-26.69% Debt Debt-to-Equity RatioN/A Current Ratio30.24 Quick Ratio30.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book5.73Miscellaneous Outstanding Shares93,399,000Free Float70,881,000Market Cap$2.42 billion OptionableOptionable Beta0.15 This page (NASDAQ:EWTX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Edgewise Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.